On April 29, 2020, the US Department of Defense (DoD) announced that it had exercised its authority under Title III of the Defense Production Act ("DPA"), 50 U.S.C. § 4501 et seq., to fund increased production capacity for swabs in light of the COVID-19 pandemic.
Section 303 of the DPA provides authority to ensure the timely availability of essential domestic industrial resources to support national defense and homeland security requirements through the use of tailored economic incentives. Authorized incentives include direct purchases and purchase commitments, development of emerging technologies, and the authority to procure and install equipment in private industrial facilities. 50 U.S.C. § 4533.
Previously in April, DoD provided $133 million in Title III contracts to bolster production of N95 respirators.
In its April 29 announcement, DoD stated that it will "invest $75.5 million" in Title III funding "to increase swab production by 20 million per month" starting in May 2020. The contract was awarded to Puritan Medical Products, which will quickly establish a new manufacturing facility capable of doubling its current monthly output of 20 million to 40 million swabs.
According to the DoD announcement, Puritan will secure a manufacturing facility in Pittsfield, Maine. Puritan will add 150 employees to staff the new factory, which is scheduled to start production in May 2020.
DoD has standing authority to use Title III and has established a program under the auspices of the Office of Industrial Policy staffed with experts to identify and support projects. Before Section 303 authorities may be used by other agencies, the President must make a (non-delegable) finding that there is a "shortfall" in the domestic industrial base for a particular type of technology or industrial capability that poses a threat to national defense. Such a shortfall determination reflects that current US industry does not have the capability to produce the needed product(s) and that the purchases, or other actions are the most effective means of meeting the need. To date, no such determination has been made for agencies outside DoD. Further use of DoD to facilitate such actions should be expected.
If you wish to receive periodic updates on this or other topics related to the pandemic, you can be added to our COVID-19 "Special Interest" mailing list by subscribing here. For any other legal questions related to this pandemic, please contact the Firm's COVID-19 Core Response Team at FW-SIG-COVID-19-Core-Response-Team@mayerbrown.com.
Article originally published on 1 May 2020
Visit us at mayerbrown.com
Mayer Brown is a global legal services provider comprising legal practices that are separate entities (the "Mayer Brown Practices"). The Mayer Brown Practices are: Mayer Brown LLP and Mayer Brown Europe - Brussels LLP, both limited liability partnerships established in Illinois USA; Mayer Brown International LLP, a limited liability partnership incorporated in England and Wales (authorized and regulated by the Solicitors Regulation Authority and registered in England and Wales number OC 303359); Mayer Brown, a SELAS established in France; Mayer Brown JSM, a Hong Kong partnership and its associated entities in Asia; and Tauil & Chequer Advogados, a Brazilian law partnership with which Mayer Brown is associated. "Mayer Brown" and the Mayer Brown logo are the trademarks of the Mayer Brown Practices in their respective jurisdictions.
© Copyright 2020. The Mayer Brown Practices. All rights reserved.
This Mayer Brown article provides information and comments on legal issues and developments of interest. The foregoing is not a comprehensive treatment of the subject matter covered and is not intended to provide legal advice. Readers should seek specific legal advice before taking any action with respect to the matters discussed herein.